C
1228
vs
H
Hang Seng (Hong Kong)
Over the past 12 months, Canbridge Pharmaceuticals Inc has significantly outperformed Hang Seng (Hong Kong), delivering a return of +1 389% compared to the Hang Seng (Hong Kong)'s +8% growth.
Stocks Performance
1228 vs Hang Seng (Hong Kong)
Performance Gap
1228 vs Hang Seng (Hong Kong)
Performance By Year
1228 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Canbridge Pharmaceuticals Inc
Glance View
CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-12-10. The firm's main businesses are the development, production, promotion and sales of medical products. The firm's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The firm's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The firm is also engaged in the development of gene therapy.
